Step therapy forces rare disease patients to fail on drugs their doctor knows won't work, causing irreversible disease progression

Step therapy -- also called "fail first" -- is an insurance cost-control practice where patients must try and fail on cheaper medications before their insurer will cover the drug their doctor actually prescribed. For common conditions like hypertension, this is annoying but rarely dangerous. For rare diseases with narrow treatment windows, it is catastrophic. A patient with a progressive neurodegenerative condition forced to spend 90 days on an ineffective first-line drug isn't just wasting time -- they're losing motor neurons, muscle function, or cognitive capacity that they will never recover. A 2016 Patients Rising survey found that 77% of patients reported that step therapy undermined their healthcare by forcing them to use ineffective treatments. The cruelty is compounded by the bureaucratic loop. When a patient fails the required drug (as their specialist predicted they would), the insurer often requires documentation of that failure -- a process that can take weeks of additional delay. In some documented cases, patients are required to fail on the same medication more than once, in direct violation of state reform laws. JP Summers, a migraine patient in Wisconsin, spent four years battling his insurance company to get approved for the medication his neurologist prescribed, cycling through cheaper alternatives that caused side effects serious enough to hospitalize him six times. The structural reason this persists is that state step therapy reform laws -- now enacted in roughly 20 states -- only apply to state-regulated insurance plans. They don't cover self-insured employer plans, which cover more than half of American workers. The federal Safe Step Act, introduced in 2023 with bipartisan support (39 Senate cosponsors, 180 House cosponsors), would establish automatic patient exemptions from step therapy in employer plans, but it has not passed. Meanwhile, a 2024 New York survey found that almost half of healthcare professionals reported insurers requiring patients to fail on the same medication more than once, and the majority did not believe existing state laws had meaningfully reduced step therapy denials. For rare disease patients whose conditions are actively progressing, every week of mandated failure is tissue damage that no subsequent treatment can reverse.